CagriSemaCombination peptide treatment in clinical research
CagriSema combines an amylin analogue with a GLP-1 receptor agonist. The central question is whether the combination improves weight and metabolic outcomes enough to justify its treatment burden.
What is CagriSema?
CagriSema is the combination of cagrilintide and semaglutide studied for weight management. It is a combination approach rather than a single peptide.
How it works
Cagrilintide provides amylin activity and semaglutide provides GLP-1 receptor activity, combining related appetite-regulation pathways.
Effects studied
Weight management without diabetes
REDEFINE 1 included 3,417 adults without diabetes. At 68 weeks, average weight change was −20.4% with the combination and −3.0% with placebo. The trial also included separate semaglutide and cagrilintide groups. 1
Evidence: These figures use the treatment-policy analysis, which accounts for treatment discontinuation. They should not be mixed with estimates assuming continued treatment, or treated as a head-to-head comparison between people with and without diabetes. 1 2
Weight management with type 2 diabetes
REDEFINE 2 enrolled 1,206 adults with type 2 diabetes and a BMI of at least 27. At 68 weeks, average weight change was −13.7% with the combination and −3.4% with placebo. Novo Nordisk funded both trials. 2
Evidence: These figures use the treatment-policy analysis, which accounts for treatment discontinuation. They should not be mixed with estimates assuming continued treatment, or treated as a head-to-head comparison between people with and without diabetes. 1 2
What does the evidence show?
REDEFINE 1 and 2 phase 3 trials; abstracts checked
Two components with complementary targets
CagriSema is the name used for cagrilintide together with semaglutide. Cagrilintide acts through amylin-related signalling; semaglutide activates the GLP-1 receptor. Both influence appetite and meal-related physiology, but combining them creates a treatment that needs its own evidence.
Why comparison groups matter
REDEFINE 1 included 3,417 adults without diabetes. At 68 weeks, average weight change was −20.4% with the combination and −3.0% with placebo. The trial also included separate semaglutide and cagrilintide groups. 1
REDEFINE 2 enrolled 1,206 adults with type 2 diabetes and a BMI of at least 27. At 68 weeks, average weight change was −13.7% with the combination and −3.4% with placebo. Novo Nordisk funded both trials. 2
Reading the headline percentage
These figures use the treatment-policy analysis, which accounts for treatment discontinuation. They should not be mixed with estimates assuming continued treatment, or treated as a head-to-head comparison between people with and without diabetes. 1 2
Benefit includes staying on treatment
Gastrointestinal events were reported by 79.6% on the combination versus 39.9% on placebo in REDEFINE 1, and 72.5% versus 34.4% in REDEFINE 2. Most were temporary and mild or moderate. The trials do not establish the quality or safety of a self-mixed preparation. 1 2
Safety & status
Gastrointestinal events were reported by 79.6% on the combination versus 39.9% on placebo in REDEFINE 1, and 72.5% versus 34.4% in REDEFINE 2. Most were temporary and mild or moderate. The trials do not establish the quality or safety of a self-mixed preparation. 1 2
Country and product status
Country-specific product availability and authorisation require a separate current check.
Frequently asked questions
Is CagriSema another name for cagrilintide?
No. It contains both cagrilintide and semaglutide.
Why can one trial report different weight-loss figures?
Different analysis approaches can handle stopping treatment or missing observations differently; those definitions need to accompany the figure.
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Garvey et al. (2025): Cagrilintide–semaglutide in adults with overweight or obesity; REDEFINE 1 Primary research · PubMed abstract; full paper and supplements not reviewed; checked 2026-10-29
- Davies et al. (2025): Cagrilintide–semaglutide in adults with overweight or obesity and type 2 diabetes; REDEFINE 2 Primary research · Abstract on first page; not full-text review; checked 2026-10-29
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.